Please assess the completion status of the following clinical trial:

Trial Title: Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with relapsed or refractory CD19-positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options.~* Estimated life expectancy ≥ 12 weeks~* Lansky (age \< 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at time of assent/consent) performance status ≥ 50~Exclusion Criteria:~* Burkitt leukemia~* CD19-negative B-cell leukemia~* Active Central Nervous System (CNS) leukemia~* Active acute or chronic Graft-versus-Host Disease (GvHD) requiring systemic use therapy within 4 weeks before UCART19 infusion~* Patients with autoimmune disease requiring systemic immunosuppression therapy that cannot be stopped~* History of CRS grade 4 related to previous CAR T cell therapy~* Contraindication to Alemtuzumab administration

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- UCART19 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).